These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 4340971)

  • 1. Prevention of neural and muscular lesions during hyperthermic regional perfusion.
    Schraffordt Koops H
    Surg Gynecol Obstet; 1972 Sep; 135(3):401-3. PubMed ID: 4340971
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperthermic perfusion with chemotherapy for cancers of the extremities.
    Stehlin JS
    Surg Gynecol Obstet; 1969 Aug; 129(2):305-8. PubMed ID: 5815841
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytotoxics and hyperthermic perfusion: a preliminary study.
    Tonak J; Hermanek P; Banz H; Groitl H
    Cancer Treat Rev; 1979 Jun; 6 Suppl():135-41. PubMed ID: 498167
    [No Abstract]   [Full Text] [Related]  

  • 4. Results of hyperthermic perfusion for melanoma of the extremities.
    Stehlin JS; Giovanella BC; de Ipolyi PD; Muenz LR; Anderson RF
    Surg Gynecol Obstet; 1975 Mar; 140(3):339-48. PubMed ID: 1114425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blood changes in hyperthermic perfusion with chemotherapeutic preparations].
    Voronko EA; Fradkin SZ
    Vopr Onkol; 1974; 20(1):98. PubMed ID: 4216151
    [No Abstract]   [Full Text] [Related]  

  • 6. [Regional hyperthermic perfusion in malignant melanoma of the extremities--controlled studies (proceedings)].
    Hafström L; Jönsson PE
    Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 723351
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs.
    Vrouenraets BC; Eggermont AM; Klaase JM; Van Geel BN; Van Dongen JA; Kroon BB
    Eur J Surg Oncol; 1994 Dec; 20(6):681-5. PubMed ID: 7995421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
    Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
    Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common peroneal nerve palsy following TNF-based isolated limb perfusion for irresectable extremity desmoid tumor.
    Drouet A; Le Moigne F; Have L; Blondet R; Jacquin O; Chauvin F
    Orthop Traumatol Surg Res; 2009 Dec; 95(8):639-44. PubMed ID: 19944662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
    Lejeune FJ; Eggermont AM
    J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
    [No Abstract]   [Full Text] [Related]  

  • 12. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral nerve damage following isolated extremity perfusion with cis-platinum.
    Busse O; Aigner K; Wilimzig H
    Recent Results Cancer Res; 1983; 86():264-7. PubMed ID: 6316430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Various aspects of treatment of primary melanoblastoma of the extremities by regional perfusion].
    Schraffordt Koops H; Eibergen R; Oldhoff J; van der Ploegen E; Vermey A
    Ned Tijdschr Geneeskd; 1975 Nov; 119(45):1746-53. PubMed ID: 1214883
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuropathy long before Waldenström's disease: effect of prolonged treatment with melphalan].
    Saric R; Moreau F; Tignol J
    J Med Bord; 1967 Sep; 144(9):1301-11. PubMed ID: 4317733
    [No Abstract]   [Full Text] [Related]  

  • 17. Soft tissue disorders of the upper extremities.
    Travers PH
    Occup Med; 1988; 3(2):271-83. PubMed ID: 2836958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regional hyperthermic perfusion with cytostatic agents in malignant melanoma of the extremities (author's transl)].
    Ghussen F; Nagel K; Groth W
    Dtsch Med Wochenschr; 1981 Nov; 106(48):1612-5. PubMed ID: 7308000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined treatment of malignant tumors of the extremities. Regional perfusion chemotherapy].
    Kolessov VI; Levin AO
    Minerva Med; 1970 Sep; 61(71):3673-5. PubMed ID: 4989391
    [No Abstract]   [Full Text] [Related]  

  • 20. [Regional hyperthermic cytostatic perfusion as an alternative in the treatment of malignant soft tissue tumors of the extremities].
    Ghussen F; Nagel K
    Chirurg; 1984 Aug; 55(8):505-7. PubMed ID: 6488995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.